Wojciechowski, Jessica http://orcid.org/0000-0002-3302-8742
S Purohit, Vivek
Huh, Yeamin
Banfield, Christopher
Nicholas, Timothy
Clinical trials referenced in this document:
Documents that mention this clinical trial
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
https://doi.org/10.1007/s40262-023-01318-3
Documents that mention this clinical trial
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
https://doi.org/10.1007/s40262-023-01318-3
Documents that mention this clinical trial
IBD therapeutics: what is in the pipeline?
https://doi.org/10.1136/flgastro-2022-102130
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
https://doi.org/10.1007/s40262-023-01318-3
Documents that mention this clinical trial
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
https://doi.org/10.1007/s40262-023-01318-3
Documents that mention this clinical trial
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
https://doi.org/10.1007/s40262-023-01318-3
Documents that mention this clinical trial
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
https://doi.org/10.1007/s40257-024-00846-3
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
https://doi.org/10.1007/s40262-023-01318-3
Documents that mention this clinical trial
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
https://doi.org/10.1007/s40262-023-01318-3
Documents that mention this clinical trial
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
https://doi.org/10.1007/s40262-023-01318-3
Documents that mention this clinical trial
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
https://doi.org/10.1007/s40262-023-01318-3
Documents that mention this clinical trial
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
https://doi.org/10.1007/s40262-023-01318-3
Documents that mention this clinical trial
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
https://doi.org/10.1007/s40262-023-01318-3
Documents that mention this clinical trial
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
https://doi.org/10.1007/s40257-024-00846-3
New drugs under investigation for the treatment of alopecias
https://doi.org/10.1080/13543784.2019.1568989
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
https://doi.org/10.1007/s40262-023-01318-3
Funding for this research was provided by:
Pfizer
Article History
Accepted: 4 October 2023
First Online: 2 November 2023
Declarations
:
: This study was funded by Pfizer Inc.
: Jessica Wojciechowski, Vivek Purohit, Yeamin Huh, Christopher Banfield, and Timothy Nicholas are employees of and hold stock in Pfizer.
: The study protocols were approved by the Institutional Review Boards/Ethics Committees of the study sites. The studies were conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and conducted according to the International Conference on Harmonization Guidelines for Good Clinical Practice.
: All participants provided written informed consent.
: Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See ExternalRef removed for more information.
: Not applicable.
: Wrote the manuscript: JW. Designed the research: JW, VSP, YH, CB, TN. Performed the research: JW, VSP, YH, CB. Analyzed the data: JW, VSP, YH, CB, TN.
: Consent to Publish. Patients signed informed consent regarding publishing their data.